Lantheus Holdings (LNTH) Tops Q1 EPS by 6c, Revenues Beat; Raises FY21 EPS/Revenues Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Lantheus Holdings (LNTH) Announces EXINI Diagnostics AB Receives CE Mark Clearance for aPROMISE in Europe
May 3, 2021 8:35 AM EDTEXINI Diagnostics AB, a subsidiary of Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence (AI) solutions to Find, Fight and Follow serious medical conditions, announced today that it has received CE Mark clearance for aPROMISE in Europe.
aPROMISE is artificial intelligence-based, deep learning-enabled, medical device software that allows healthcare professionals and researchers to perform quantitative assessment of prostate-specific... More
Lantheus (LNTH) Grants AHN Exclusive Rights for Use of Microbubbles in Combination with Ultrasound Assisted Gene Therapy for Development of Proposed Treatment for Xerostomia
April 30, 2021 8:33 AM EDTLantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced a strategic collaboration with Allegheny Health Network (AHN), a western Pennsylvania healthcare delivery system headquartered in Pittsburgh, PA. Under the agreement, Lantheus microbubbles will be used in combination with AHNs ultrasound-assisted non-viral gene transfer (UAGT) technology for the development of a proposed treatment for xerostomia.
Xerostomia, a lack of saliva production leading to dry mouth, has a variety of causes,... More
